TTRX earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -52.94. Updated 2026-07-23.
Turn Therapeutics (TTRX) Research Hub
Turn Therapeutics (TTRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 12.69 USD (-7.71%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -52.94, market cap 0.30B. This hub links to the full technical, earnings and options research available for TTRX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 12.69 USD (-7.71%) |
| 52-week range | 5.55 USD – 14.39 USD |
| Trend regime | Range |
| 14-day RSI | 65.9 (Bullish) |
| Trailing P/E | -52.94 |
| Market cap | 0.30B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for TTRX
Covered Call on TTRX: how it works, illustrative setup around the real 12.69 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TTRX: how it works, illustrative setup around the real 12.69 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TTRX: how it works, illustrative setup around the real 12.69 USD price, max profit/loss, breakeven and when to use it. Educational.
TTRX technical analysis: range, last 12.69 USD, RSI 65.9, 52w range 5.55 USD–14.39 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TTRX in?
Turn Therapeutics (TTRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TTRX in an uptrend or downtrend?
As of 2026-09-11, TTRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TTRX's trailing P/E ratio?
TTRX's trailing P/E is -52.94, with a market cap of 0.30B. See the earnings research page for full valuation detail.
When does TTRX next report earnings?
TTRX is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.03 USD.